ARS Pharmaceuticals, Inc.

Fundamentals5.0
Price Action6.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • High gross margin
  • Large cash burn
  • Reliance on funding

AI
AI Summary

6.0

SPRY has shifted from a binary clinical gamble to a commercialization-first company with meaningful first‑year U.S. neffy revenue and attractive product gross margins, making valuation hinge on execution of payer access, refill durability, and rapid SG&A/CAC improvement to hit cash‑flow breakeven. If management can demonstrably improve gross‑to‑net and cut CAC or show sustained refill retention, the stock re-rates positively; if payer friction, ~50% net retention, or high SG&A persist, expect dilution and multiple compression.

CommercialMomentum
PayerRisk
CashFlow‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

5.0

Key Financial Insights:

  • High gross margin
  • Large cash burn
  • Reliance on funding

Spry has strong unit economics and near-term liquidity but is losing substantial cash due to outsized SG&A and heavy free‑cash‑flow burn, forcing reliance on external funding and leaving valuation rich for a loss-making company.

StrongLiquidity
HighBurn

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below last-month average
  • Near-term support
  • Resistance ~10–15% up

SPRY is trading below its last-month average (~$8.84) at $8.17, showing a short-term downtrend but sitting on a near-term support band around $8.17–$8.90 with resistance near $9.17–$9.30 that must be cleared for a reversal.

downtrend
support
Support Level: $8.17–$8.90
Resistance Level: $9.17–$9.30

Steady decline from ~ $9.30 to $8.17 since early

Sentiment & News

6.0

Key News Insights:

  • neffy first-year sales
  • heavy SG&A
  • $245M cash

ARS Pharmaceuticals posted in-line Q4 results with $72.2M in first-year neffy U.S. sales but faces a slow launch, heavy SG&A and a large 2025 loss despite $245M cash, ongoing clinical progress and notable institutional buying.

neffy
profitability

Mixed commercial traction and strong cash give upside if launches and Phase 2b readout accelerate, but near-term valuation is constrained by burn and slow revenue ramp